Skip to content

Effects of Intact and Disrupted Milk Fat Globule Membrane on Postprandial Metabolic Response to High-fat Dairy in Healthy Individuals

Effects of Intact and Disrupted Milk Fat Globule Membrane on Postprandial Metabolic Response to High-fat Dairy in Healthy Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06340412
Enrollment
12
Registered
2024-04-01
Start date
2024-03-11
Completion date
2025-03-01
Last updated
2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Lipid Metabolism

Keywords

Milk fat globule membrane

Brief summary

The aim of the study is to investigate the effects of milk fat globule membrane (MFGM) content and intactness on postprandial metabolic response to a high-fat meal in humans. The investigators hypothesize that MFGM content and intactness alters the postprandial lipid profile and substrate metabolism in healthy individuals after consumption of a high-fat meal.

Detailed description

The subjects will be invited for four visits in total: one screening visit and three test days separated by a one-week washout period. At the test days, subjects will consume two high-fat meals composed of milk fat with intact MFGM, destroyed MFGM, and without MFGM, respectively. The first meal will be consumed as breakfast and the second meal will be consumed as lunch. Test meals will be isocaloric and with similar macronutrient composition. The meal will consist of a sandwich with a butter-like dairy product. The three trial days will be completely alike, besides the interventions. Subjects will arrive at the research lab the night before test day and stay inside a metabolic chamber to acclimatize. The participants will have one intravenous (iv.) access placed in the elbow on the three trial days where blood samples will be collected at 15, 30, 60, 90, 120, 150 and 180 min after each test meal (breakfast and lunch). Immediately after consuming each of the two test meals, the subjects will take 1,500mg paracetamol to determine ventricular emptying rate using the acetaminophen test. After this, the subjects can lay in the bed and watch TV, iPad, or work on their laptop. Before and every hour after consumption of the test meals, the subjects will be asked to fill out an appetite questionnaire (visual analogue scale). At the end of the day the participants will be offered an ad libitum meal to measure if MFGM content and intactness influences ad libitum intake of calories at the next meal. An one-way mixed model of linear regression will be used to compare postprandial area under the curve, ventricular emptying, and ad libitum food intake between the three test days. Secondary outcomes will be analyzed using a two-way mixed model of linear regression with repeated measurements. Based on the results from a previous study that investigated the effects of the fat and protein structure in dairy products on postprandial triglycerides (20), the investigators will need 11 subjects to detect a 15% decrease in postprandial triglyceride AUC (α=0.05, β=0.80). To account for potential missing values, 12 subjects will be included in total.

Interventions

DIETARY_SUPPLEMENTSandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.

1\) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.

DIETARY_SUPPLEMENTSandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.

2\) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.

DIETARY_SUPPLEMENTSandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.

3\) Sandwich with butter-like dairy product (40g milk fat) without MFGM.

Sponsors

Arla Foods
CollaboratorINDUSTRY
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

A randomized, double-blinded, controlled, crossover trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-40 years * Written and informed consent * HbA1c \< 48 mmol/l

Exclusion criteria

* Medicine with an impact on blood glucose, lipid profile, or blood pressure and birth control pills * BMI \> 30kg/m2 * Affected screening blood sample as evaluated by the clinical responsible investigator * Severe claustrophobia * Lactose intolerance * Doesn't speak and understand Danish * Commitment to special diets

Design outcomes

Primary

MeasureTime frameDescription
Difference in postprandial triglycerides measured as area under the curve (AUC).-60 to 180 minutes after first intervention (first meal), 0-180 minuter after second intervention (second high-fat meal)Difference in triglycerides AUC after the intervention between high-fat meal with intact MFGM, high-fat meal with destroyed MFGM, and high-fat meal without MFGM.

Secondary

MeasureTime frameDescription
Difference in concentration of Ghrelin-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of LEAP2-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of FFA-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of Insulin-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of glucagon-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of cholesterol (total, LDL and HDL)-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of GIP-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of CCK-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration concentration of Gastrin-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration concentration of GDF15-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of GLP-1-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration concentration of Cytokines-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of apoB48-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in concentration of apoB100-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)
Difference in glucose concentration-60 to 360 minutes after first intervention (first high-fat meal)Continuous glucose monitoring (CGM)
Difference in appetite sensation-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)Visual analogue scale (VAS)
Difference in gastric emptying rate-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)Acetaminophen test
Ad libitum meal test420 minutes after start of test day.Amount of food (in grams) intake at the end of the test day to measure if MFGM content and intactness influences ad libitum intake of calories at the next meal.
Metabolic rate0-420 minutesIndirect calorimetry
Substrate metabolism0-420 minutesIndirect calorimetry
Difference in concentration of LPS-BP (Lipopolysaccharide Binding Protein)-60 to 180 minutes after first intervention (first high-fat meal), 0-180 minutes after second intervention (second high-fat meal)

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026